HivPhase 1NCT05903339
Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV
A Phase 1 study testing V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg and Alum 500 mcg in people with Hiv, run by National Institute of Allergy and Infectious Diseases (NIAID) at 6 sites in United States.
Trial summary
This first-in-human (FIH) phase 1 clinical trial will evaluate a prime-boost regimen of immunogens designed to induce HIV-1 Env V3-glycan-specific broadly neutralizing antibodies (V3G bNAbs). The priming immunogen (V3G CH848 Pr-NP1) consists of ferritin NPs expressing 8 copies of an Env trimer. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Hiv
- What is being tested?
- V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg and Alum 500 mcg
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 6 sitesUnited States
- Study dates
- 29 Aug 2023to 18 Dec 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Able and willing to complete the informed consent process, including an Assessment of Understanding (AoU): Volunteer demonstrates an understanding of this study and completes a questionnaire prior to first vaccination with verbal demonstration of understanding of questionnaire items that were answered incorrectly.
- 18 to 55 years old, inclusive, on day of enrollment.
- Available for clinic follow-up through the last clinic visit, willing to undergo lymph node fine needle aspiration and leukapheresis, and willing to be contacted 12 months after the last study-product administration.
- Agrees not to enroll in another study of an investigational agent during participation in the trial. If a potential participant is already enrolled in another clinical trial, approvals from the other trial sponsor and the HVTN 307 PSRT are required prior to enrollment into HVTN 307.
- In good general health according to the clinical judgment of the site investigator.
- Physical examination and laboratory results without clinically significant findings that would interfere with assessment of safety or reactogenicity in the clinical judgement of the site investigator.
Show all 29Show fewer
- Assessed by clinical staff as having a low likelihood of acquiring HIV per guidelines, agrees to discuss their potential for HIV acquisition, agrees to risk-reduction counseling, and agrees to avoid behaviors associated with a higher likelihood of acquiring HIV through the final study visit. Low likelihood may include persons stably taking pre-exposure prophylaxis (PrEP) as prescribed.
- Hemoglobin (Hgb):
- ≥ 11.0 g/dL for volunteers AFAB
- ≥ 13.0 g/dL for volunteers AMAB and for volunteers AFAB or intersex at birth who have been on masculinizing hormone therapy for more than 6 consecutive months
- ≥ 12.0 g/dL for volunteers AMAB or intersex at birth who have been on feminizing hormone therapy for more than 6 consecutive months
- For transgender or intersex volunteers who have been on hormone therapy for less than 6 consecutive months, determine Hgb eligibility based on their sex assigned at birth
- WBC count = 2,500 to 12,000/mm3 (WBC over 12,000/mm3 is not exclusionary if further evaluation shows general good health and if PSRT approval is granted).
- Platelets = 125,000 to 550,000/mm3.
- Alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) based on the institutional normal range.
- Serum creatinine ≤ 1.1 x ULN based on the institutional normal range.
- A minimum limit of 8.5 mg/dL for corrected total serum calcium.
- Systolic blood pressure of 90 to <140 mmHg and diastolic blood pressure of 50 to <90 mmHg at screening visit. The average blood pressure between the screening visit and the enrollment visit must be below 140 mmHg systolic and 90 mmHg diastolic. A single measurement greater than or equal to 160 systolic mmHg or 100 mmHg diastolic during the current study evaluation is exclusionary.
- Negative HIV test results by one of the following options:
- For US volunteers:
- US Food and Drug Administration (FDA)-approved enzyme immunoassay (EIA)
- Chemiluminescent microparticle immunoassay (CMIA)
- Two negative results on HIV rapid tests (one of which must be FDA-approved CMIA)
- Negative for anti-Hepatitis C virus (HCV) Abs (anti-HCV) or negative HCV nucleic acid test (NAT) if anti-HCV Abs are detected.
- Negative for Hepatitis B surface antigen.
- For volunteers AFAB or intersex at birth and are of reproductive potential (hereafter referred to as "persons of pregnancy potential"):
- Must agree to use effective means of birth control from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination timepoint.
- Must have a negative beta human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on day of enrollment.
- Volunteers of pregnancy potential must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination timepoint.
Who cannot join
- Volunteer who is breastfeeding or pregnant.
- Body mass index (BMI) ≥ 40. Enrollment of individuals with BMI ≥ 40, whom the site investigator assesses are in good health, may be considered by PSRT approval.
- Diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by HgbA1c ≤ 8% within the last 6 months) or a history of isolated gestational diabetes are not exclusionary. Enrollment of individuals with Type 2 DM that is well controlled on hypoglycemic agent(s) may be considered by the PSRT on a case-by-case basis, provided that the HgbA1c is ≤ 8% within the last 6 months (sites may draw these at screening).
- Previous or current recipient of an investigational HIV vaccine (previous placebo/ control recipients are not excluded).
- Receipt of non-HIV experimental vaccine(s) received within the last 1 year. Exceptions include vaccines that have subsequently undergone licensure or Emergency Use Authorization (EUA) by the FDA or World Health Organization (WHO) emergency use listing (EUL), or if outside the US, by the national Regulatory Authority (RA) authorizing this clinical trial.
- Congenital or acquired immunodeficiency, including systemic medication use likely to impair immune response to vaccine in the opinion of the site investigator, such as glucocorticoid use, equal to or greater than prednisone 10 mg/day within 3 months prior to enrollment.
Show all 32Show fewer
- Blood products or immunoglobulin within 16 weeks prior to enrollment; receipt of immunoglobulin within 16 weeks prior to enrollment requires PSRT approval.
- Receipt of any of the following within 4 weeks prior to enrollment;
- Live replicating vaccines
- Any mRNA-based vaccine with FDA licensure, FDA emergency use authorization (EUA), or World Health Organization (WHO) emergency use listing
- ACAM2000 vaccine > 28 days prior with a vaccination scab still present.
- Receipt of any vaccines that are not covered in #8 within 14 days prior to enrollment. Please note this includes replication incompetent vaccines such as the Jynneos vaccine for the prevention of mpox (formerly known as monkeypox) disease.
- Initiation of antigen-based immunotherapy for allergies within the previous year (stable immunotherapy is not exclusionary); inclusion of participants who initiated immunotherapy within the previous year requires PSRT approval.
- Receipt of investigational research agents with a half-life of 7 or fewer days within 4 weeks prior to enrollment. If a potential participant has received investigational agents with a half-life of greater than 7 days (or unknown half-life) within the past year, PSRT approval is required for enrollment.
- History of serious reaction (eg, hypersensitivity, anaphylaxis) to any related vaccine or component of the study-vaccine regimen. Of note, the study proposed vaccine regimen includes components similar to components of the licensed COMIRNATY (Pfizer) and SPIKEVAX (Moderna) mRNA vaccines; severe reaction to these vaccines is therefore exclusionary.
- Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.
- Idiopathic urticaria within the past year.
- Bleeding disorder diagnosed by a clinician which would make study procedures a contraindication.
- Seizure disorder; febrile seizures as a child or seizures secondary to alcohol withdrawal more than 5 years ago are not exclusionary.
- Asplenia or functional asplenia.
- Active duty and reserve US military personnel.
- Any other chronic or clinically significant condition that, in the clinical judgement of the investigator, would jeopardize the safety or rights of the study participant, including but not limited to: clinically significant forms of substance use or alcohol use disorder(s), serious psychiatric disorders, persons with any suicide attempt within the past 1 year (if between 1 and 2 years, consult PSRT for approval), or cancer that, in the clinical judgement of the site investigator, has potential for recurrence (excluding basal cell carcinoma).
- Asthma is excluded if the participant has ANY of the following:
- Required either oral or parenteral corticosteroids for an exacerbation 2 or more times within the past year; OR
- Needed emergency care, urgent care, hospitalization, or intubation for an acute asthma exacerbation within the past year (eg, would NOT exclude individuals with asthma who meet all other criteria but sought urgent/emergent care solely for asthma medication refills or coexisting conditions unrelated to asthma); OR
- Uses a short-acting rescue inhaler more than 2 days/week for acute asthma symptoms (ie, not for preventive treatment prior to athletic activity); OR
- Uses medium-to-high-dose inhaled corticosteroids (greater than 250 mcg fluticasone or therapeutic equivalent per day), whether in single-therapy or dual-therapy inhalers (ie, with a long-acting beta agonist [LABA]); OR
- Uses more than 1 medication for maintenance therapy daily. Inclusion of anyone on a stable dose of more than 1 medication for maintenance therapy daily for greater than 2 years requires PSRT approval.
- A participant with a history of a potential immune-mediated medical condition (PIMMC), either active or remote. Specific examples are listed in Appendix F (AESI Index). Not exclusionary: 1) Remote history of Bell's palsy (> 2 years ago) not associated with other neurologic symptoms and 2) mild psoriasis that does not require ongoing systemic treatment.
- History of allergy to local anesthetic (Novocaine, Lidocaine).
- Investigator concern for difficulty with venous access based on clinical history and physical examination. For example, persons with a history of intravenous drug use or substantial difficulty with previous blood draws.
- History of myocarditis and/or pericarditis
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
United States6 sites
Emory University School of Medicine, The Ponce de Leon Center CRS [Site ID: 5802]
Atlanta, Georgia, 30303
Alabama CRS [Site ID: 31788]
Birmingham, Alabama, 35294-2170
Brigham & Women's Hospital [Site ID: 30007]
Boston, Massachusetts, 02115
BIDMC VCRS [Site ID: 32077]
Boston, Massachusetts, 02215
Vanderbilt Vaccine (VV) CRS [Site ID: 30352]
Nashville, Tennessee, 37232-2582
Seattle Vaccine and Prevention CRS [Site ID: 30331]
Seattle, Washington, 98104
About this study
Official title: A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV
This first-in-human (FIH) phase 1 clinical trial will evaluate a prime-boost regimen of immunogens designed to induce HIV-1 Env V3-glycan-specific broadly neutralizing antibodies (V3G bNAbs). The priming immunogen (V3G CH848 Pr-NP1) consists of ferritin NPs expressing 8 copies of an Env trimer. This immunogen will be boosted with an mRNA LNP (V3G CH848 mRNA-Tr2), encoding a soluble Env trimer which does not utilize the ferritin NP design.
- Conditions
- Hiv
- Being tested
- V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg, Alum 500 mcg, V3G CH848 mRNA-Tr2 50mcg, ACU-026-001-1 2.0mg
- Medical subject headings
- Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
V3G CH848 Pr-NP1 60mcgDrug
(60 mcg)
3M-052-AF 5mcgDrug
(5 mcg)
Alum 500 mcgDrug
(500 mcg)
V3G CH848 mRNA-Tr2 50mcgDrug
(50 mcg)
ACU-026-001-1 2.0mgDrug
(2.0 mg)
V3G CH848 Pr-NP1 100mcgDrug
(100 mcg)
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Low dose V3G CH848 Pr-NP1 with 3M-052-AF + Alum | Experimental | 3 doses of V3G CH848 Pr-NP1 (60 mcg) combined with 3M-052-AF (5 mcg) and Alum (500 mcg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit Receives: Drug: V3G CH848 Pr-NP1 60mcg; Drug: 3M-052-AF 5mcg; Drug: Alum 500 mcg; Drug: V3G CH848 mRNA-Tr2 50mcg |
| Group 2: Low dose V3G CH848 Pr-NP1 with ACU-026-001-1 | Experimental | 3 doses of V3G CH848 Pr-NP1 (60 mcg) combined with ACU-026-001-1 (2.0 mg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit Receives: Drug: V3G CH848 Pr-NP1 60mcg; Drug: V3G CH848 mRNA-Tr2 50mcg; Drug: ACU-026-001-1 2.0mg |
| Group 3: V3G CH848 Pr-NP1 with 3M-052-AF + Alum | Experimental | 3 doses of V3G CH848 Pr-NP1 (100 mcg) combined with 3M-052-AF (5 mcg) and Alum (500 mcg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit Receives: Drug: 3M-052-AF 5mcg; Drug: Alum 500 mcg; Drug: V3G CH848 mRNA-Tr2 50mcg; Drug: V3G CH848 Pr-NP1 100mcg |
| Group 4: V3G CH848 Pr-NP1 with ACU-026-001-1 | Experimental | 3 doses of V3G CH848 Pr-NP1 (100 mcg) combined with ACU-026-001-1 (2.0 mg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit Receives: Drug: V3G CH848 mRNA-Tr2 50mcg; Drug: ACU-026-001-1 2.0mg; Drug: V3G CH848 Pr-NP1 100mcg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Local reactogenicity signs and symptoms for a minimum of 14 days following receipt of any study vaccine
Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 (exceptions apply)
Measured: 2 weeks following any injection
Systemic reactogenicity signs and symptoms for a minimum of 14 days following receipt of any study vaccine.
Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 (exceptions apply)
Measured: 2 weeks following any injection
Number of SAEs (Serious Adverse Events) leading to early participant withdrawal or permanent discontinuation
Measured: 12 months following receipt of any study product
Number of MAAEs (medically attended adverse event) leading to early participant withdrawal or permanent discontinuation
Measured: 12 months following receipt of any study product
Number of AESIs (Adverse events of special interest) leading to early participant withdrawal or permanent discontinuation
Measured: 12 months following receipt of any study product
Number of AEs (adverse events) leading to early participant withdrawal or permanent discontinuation
Measured: 12 months following receipt of any study product
Frequency of the V3G-specific precursor IgM+ and IgG+ B cells.
Measured by flow cytometry analysis
Measured: 2 weeks following injection
Secondary outcomes (9)
Response rate of serum IgG binding Abs
Assessed by binding antibody multiplex assay (BAMA)
Measured: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Magnitude of serum IgG binding Abs
Assessed by binding antibody multiplex assay (BAMA)
Measured: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Response rate of serum IgG binding Abs
Assessed by BAMA
Measured: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Magnitude of serum IgG binding Abs
Assessed by BAMA
Measured: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Response rate of serum Ab autologous neutralization of vaccine-matched tier 2 HIV-1 strains
measured by TZM-bl pseudovirus assay
Measured: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Magnitude of serum Ab autologous neutralization of vaccine-matched tier 2 HIV-1 strains
measured by TZM-bl pseudovirus assay
Measured: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Occurrence of CD4+ T-cell responses
Assessed by intracellular cytokine staining in PMBCs
Measured: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Magnitude of CD4+ T-cell responses
Assessed by intracellular cytokine staining in PMBCs
Measured: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Response rate of CD4+ T-cell responses
Assessed by intracellular cytokine staining in PMBCs
Measured: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2023
- Study start29 Aug 2023
- Primary completion18 Dec 2026 (estimated)
- Study completion18 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HivStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05903339
- Sponsor's protocol ID
- HVTN 307
- Other IDs
- 38970
- Status last verified
- Apr 2026
- First submitted
- 5 Jun 2023
- Last updated
- 20 Apr 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV
- ClinicalTrials.gov ID
- NCT05903339
- Acronym / sponsor ID
- HVTN 307
- Conditions
- Hiv
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 36 participants (actual)
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Study start
- 29 Aug 2023 (actual)
- Primary completion
- 18 Dec 2026 (estimated)
- Study completion
- 18 Dec 2026 (estimated)
- First posted
- 15 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This first-in-human (FIH) phase 1 clinical trial will evaluate a prime-boost regimen of immunogens designed to induce HIV-1 Env V3-glycan-specific broadly neutralizing antibodies (V3G bNAbs). The priming immunogen (V3G CH848 Pr-NP1) consists of ferritin NPs expressing 8 copies of an Env trimer. This immunogen will be boosted with an mRNA LNP (V3G CH848 mRNA-Tr2), encoding a soluble Env trimer which does not utilize the ferritin NP design.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group 1: Low dose V3G CH848 Pr-NP1 with 3M-052-AF + Alum | Experimental | Drug: V3G CH848 Pr-NP1 60mcg, Drug: 3M-052-AF 5mcg, Drug: Alum 500 mcg, Drug: V3G CH848 mRNA-Tr2 50mcg3 doses of V3G CH848 Pr-NP1 (60 mcg) combined with 3M-052-AF (5 mcg) and Alum (500 mcg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit |
| Group 2: Low dose V3G CH848 Pr-NP1 with ACU-026-001-1 | Experimental | Drug: V3G CH848 Pr-NP1 60mcg, Drug: V3G CH848 mRNA-Tr2 50mcg, Drug: ACU-026-001-1 2.0mg3 doses of V3G CH848 Pr-NP1 (60 mcg) combined with ACU-026-001-1 (2.0 mg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit |
| Group 3: V3G CH848 Pr-NP1 with 3M-052-AF + Alum | Experimental | Drug: 3M-052-AF 5mcg, Drug: Alum 500 mcg, Drug: V3G CH848 mRNA-Tr2 50mcg, Drug: V3G CH848 Pr-NP1 100mcg3 doses of V3G CH848 Pr-NP1 (100 mcg) combined with 3M-052-AF (5 mcg) and Alum (500 mcg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit |
| Group 4: V3G CH848 Pr-NP1 with ACU-026-001-1 | Experimental | Drug: V3G CH848 mRNA-Tr2 50mcg, Drug: ACU-026-001-1 2.0mg, Drug: V3G CH848 Pr-NP1 100mcg3 doses of V3G CH848 Pr-NP1 (100 mcg) combined with ACU-026-001-1 (2.0 mg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (29 listed)
- Able and willing to complete the informed consent process, including an Assessment of Understanding (AoU): Volunteer demonstrates an understanding of this study and completes a questionnaire prior to first vaccination with verbal demonstration of understanding of questionnaire items that were answered incorrectly.
- 18 to 55 years old, inclusive, on day of enrollment.
- Available for clinic follow-up through the last clinic visit, willing to undergo lymph node fine needle aspiration and leukapheresis, and willing to be contacted 12 months after the last study-product administration.
- Agrees not to enroll in another study of an investigational agent during participation in the trial. If a potential participant is already enrolled in another clinical trial, approvals from the other trial sponsor and the HVTN 307 PSRT are required prior to enrollment into HVTN 307.
- In good general health according to the clinical judgment of the site investigator.
Key exclusion criteria (32 listed)
- Volunteer who is breastfeeding or pregnant.
- Body mass index (BMI) ≥ 40. Enrollment of individuals with BMI ≥ 40, whom the site investigator assesses are in good health, may be considered by PSRT approval.
- Diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by HgbA1c ≤ 8% within the last 6 months) or a history of isolated gestational diabetes are not exclusionary. Enrollment of individuals with Type 2 DM that is well controlled on hypoglycemic agent(s) may be considered by the PSRT on a case-by-case basis, provided that the HgbA1c is ≤ 8% within the last 6 months (sites may draw these at screening).
- Previous or current recipient of an investigational HIV vaccine (previous placebo/ control recipients are not excluded).
- Receipt of non-HIV experimental vaccine(s) received within the last 1 year. Exceptions include vaccines that have subsequently undergone licensure or Emergency Use Authorization (EUA) by the FDA or World Health Organization (WHO) emergency use listing (EUL), or if outside the US, by the national Regulatory Authority (RA) authorizing this clinical trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| V3G CH848 Pr-NP1 60mcg(60 mcg) | Drug | Group 1: Low dose V3G CH848 Pr-NP1 with 3M-052-AF + Alum, Group 2: Low dose V3G CH848 Pr-NP1 with ACU-026-001-1 |
| 3M-052-AF 5mcg(5 mcg) | Drug | Group 1: Low dose V3G CH848 Pr-NP1 with 3M-052-AF + Alum, Group 3: V3G CH848 Pr-NP1 with 3M-052-AF + Alum |
| Alum 500 mcg(500 mcg) | Drug | Group 1: Low dose V3G CH848 Pr-NP1 with 3M-052-AF + Alum, Group 3: V3G CH848 Pr-NP1 with 3M-052-AF + Alum |
| V3G CH848 mRNA-Tr2 50mcg(50 mcg) | Drug | Group 1: Low dose V3G CH848 Pr-NP1 with 3M-052-AF + Alum, Group 2: Low dose V3G CH848 Pr-NP1 with ACU-026-001-1, Group 3: V3G CH848 Pr-NP1 with 3M-052-AF + Alum, Group 4: V3G CH848 Pr-NP1 with ACU-026-001-1 |
| ACU-026-001-1 2.0mg(2.0 mg) | Drug | Group 2: Low dose V3G CH848 Pr-NP1 with ACU-026-001-1, Group 4: V3G CH848 Pr-NP1 with ACU-026-001-1 |
| V3G CH848 Pr-NP1 100mcg(100 mcg) | Drug | Group 3: V3G CH848 Pr-NP1 with 3M-052-AF + Alum, Group 4: V3G CH848 Pr-NP1 with ACU-026-001-1 |
Primary outcome
Local reactogenicity signs and symptoms for a minimum of 14 days following receipt of any study vaccine
Time frame: 2 weeks following any injection
Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 (exceptions apply)
Systemic reactogenicity signs and symptoms for a minimum of 14 days following receipt of any study vaccine.
Time frame: 2 weeks following any injection
Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 (exceptions apply)
Number of SAEs (Serious Adverse Events) leading to early participant withdrawal or permanent discontinuation
Time frame: 12 months following receipt of any study product
Number of MAAEs (medically attended adverse event) leading to early participant withdrawal or permanent discontinuation
Time frame: 12 months following receipt of any study product
Number of AESIs (Adverse events of special interest) leading to early participant withdrawal or permanent discontinuation
Time frame: 12 months following receipt of any study product
Number of AEs (adverse events) leading to early participant withdrawal or permanent discontinuation
Time frame: 12 months following receipt of any study product
Frequency of the V3G-specific precursor IgM+ and IgG+ B cells.
Time frame: 2 weeks following injection
Measured by flow cytometry analysis
9 secondary outcomes
Response rate of serum IgG binding Abs
Time frame: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Magnitude of serum IgG binding Abs
Time frame: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Response rate of serum IgG binding Abs
Time frame: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Magnitude of serum IgG binding Abs
Time frame: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Response rate of serum Ab autologous neutralization of vaccine-matched tier 2 HIV-1 strains
Time frame: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Magnitude of serum Ab autologous neutralization of vaccine-matched tier 2 HIV-1 strains
Time frame: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Occurrence of CD4+ T-cell responses
Time frame: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Magnitude of CD4+ T-cell responses
Time frame: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Response rate of CD4+ T-cell responses
Time frame: 2 weeks after the priming regimen and 2 weeks after the boost with V3G CH848 mRNA-Tr2
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Hiv
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg and Alum 500 mcg in people with Hiv, run by National Institute of Allergy and Infectious Diseases (NIAID) at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 29 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Local reactogenicity signs and symptoms for a minimum of 14 days following receipt of any study vaccine (time frame: 2 weeks following any injection). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2026.